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Seroprevalence of Herpes viruses in a 
retrospective study in Southern Italy
Abstract
Information on age- and sex-specific prevalence of herpes viruses (HHV) is of 
importance to optimize control and prevention strategies. Using data from a 
population-based serological study in South Italy (n=1854) between 1/01/2016 
and 30/06/2017, the main purpose of the present study was to assess the 
spread of HSV1-2, VZV and CMV seroprevalence in a random population. 
Results of seroprevalence in South Italy in the last year showed that CMV is the 
most frequent species with a significantly higher prevalence in women , and 
with infection rates increasing from childhood to adolescence. In our country, 
probability of seropositivity for HSV1-2 infections increase with age. A large 
proportion of teenagers and young adults remain HSV-1-2 susceptible and women 
were significantly more likely to be HSV1-2 seropositive. Similar to other European 
countries, varicella immunity in south Italy is acquired gradually, starting in early 
childhood and showing an increase around age 3–5 years even if the amount of 
susceptible adults aged over 20 years is still substantial.
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Introduction
Human Herpes viruses (HHVs) are pathogens affecting 60-95% of 
the population worldwide with an ubiquitous distribution even  if 
a great importance has been  identified with geografic location, 
socioeconomic status and age to value the primary infection’s 
acquisition. Primary infection is followed by a latency phase in 
the host and by possible periodical reactivated infections. During 
latent infections, viruses involve different tissues concerning 
viral species interested: sensor ganglia for HSV1, HSV2 and VZV; 
limphocytes, monocytes and epithelium for EBV, CMV and HSV6-
8. HHVs have been also linked to the development of chronic 
disorder as Alzhemeir’s disease, cardiovascular disease and 
depression.
There are two types of HSV, HSV1 and HSV2, transmitted by 
direct contact with infected secretions. HSV1 is transmitted by 
direct contact with infected secretions, locaized  predominantly 
in orolabial ulceration even if many infections remain 
asymptomaytic and, therefore, so undiagnosed. Typically, clinical 
lesions occur after a primary infection. Seroprevalence rates 
of HVS1 varied from 50-85% or more in adults from developed 
country in Europe, while, epidemiological studies, in Italy, 
showed a seroprevalence rates of 93% in the adult population 
[1]. HSV-2 is transmitted sexually and is one of the most common 
genital diseases, affecting adolescents and adults and faciliting 
HIV transmission. The circulation of HSV-2 is more limited, 
and is generally, associated with other sexually transmitted 
diseases affecting about 5% of the adult population in Italy 
[2-5]. Monitoring the epidemiology of HSV1-2 infections is of 
importance for the prevention of neonatal herpes and associated 
diseases and for determining antibody prevalence in the general 
population.
As regards primary varicella infection, this is considered a benign 
common  illness of child with a life-long immunity that, in later 
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life, could reactivate and cause herpes zoster. Although mortality 
is rare, varicella is more severe in old ages, pregnant women, 
neonates and immunocompromised individuals [6-8]. A live 
attenuated vaccine was developed in 1970s and an evaluation 
of vaccination plans in the United States reported a decrease in 
disease, hospitalisation and mortality but the age of infection 
increased with an increase of severe cases.  Routine vaccination 
against VZV has been recently introduced in Italy recently as a 
national immunization programme, while was only reccomanded 
for non-immunized  individual in the past. So there isn’t an 
evaluation of its efficacy and we need epidemiological data to 
identify risk associated with VZV seronegativity. It’s important 
to consider that seropositivity in adult population and high risk 
of infection in young children is typical in Italy such as other 
countries with temperate climate [9].
Human cytomagalovirus (CMV) is a highly prevalent herpes 
virus that infect 30-100% of population worldwide. Even if it 
is considered a benign infection, sometimes it causes serious 
diseases in immunocompromised patients and pregnant women 
with an active infection, but also in healthy people playing an 
important role in aging of the immune system. It is the most 
common congenital infection transmitted by maternal infection 
or reactivation. Early childhood  infection  is asymptomatic or 
causes a flu-like symtoms. Seroprevalence is around 40-50 % 
among white populations and higher about 80-100% in some 
non-white populations. [10,11]
To update the epidemiology of HHV infections in southern Italy, 
an epidemiological study was carried out to determine the 
seroprevalence of HSV1-2, VZV, CMV among a general population 
who asked for hospital care to the University Hospital Vanvitelli 
in the last past year.
Materials and Methods
Study design
A seroprevalence retrospective study from a general population 
was carried out using sera collected from patients of all ages 
(1-70 years) hospitalized at the University Hospital Vanvitelli in 
Naples Italy for different causes. During a period from 1/01/2016 
to 30/06/2017, 1854 patients’s sera were analysed for detection 
of type-specific HSV1-2 antibodies using Elisa (Kit Instituit Virion/
Serion GmbH Ref ESR 105G-105M), CMV antibodies  using 
enzyme immunoassay Biomerieux Vidas, IgG Ref 30204-IgM REF 
30205), VZV antibodies using chemiluminescence immunoassay 
(Gemini Combo Alifax, IgG REF ESR 04 – IgM REF ESR 104) 
following manifacturer’s instructions.
Seropositivity was defined as follows according to the provider of 
the assay: VZV IgG measurement lower than 50 U/µl should be 
considered uninfected, while samples with measurement grater 
or equal than 100U/µl should be classified as infected; HSV1 IgG 
lower than 20 U/µl uninfected while grater or equal than 30 U/
µl infected; CMV IgG lower than 0,7 U/µl uninfected, reater or 
equal than 0,90 U/µl infected.
Statistical Data
Seroprevalences by age-group were tabulated with 95% 
confidence interval (CI) and comparison of differences between 
seropositive and seropositive subjects was performed using 
the Chi-squared test (χ2). Odds ratios (OR) were calculated 
with multiple logistic regression analysis of risk factors age and 
gender identified from the literature as potential risk factors for 
seroprevalence. Data were analysed using using Statistic Toolbox 
in the Matlab Environment.
Results 
The seroprevalence of IgG antibodies towards three of common 
human herpes viruses were respectively investigated. Population 
characteristics related to HSV1-2, VZV, CMV seroprevalence were 
reported in Table 1. Within total group of 1854 patients, 1149 
were analized for HSV1-2, 895 for VZV and 1529 for CMV. The 
results for HSV1-2 antibodies detection were reported in Table 1. 
762 patients were seropositive (66%)  and 387 were seronegative 
for HSV1-2 with the mean age of 32.4 and 31.4 respectively. As 
reported in Table 2 with the HSV1-2 seropositive men were 341 
(45%) and women 421 (55%) with a mean age of 32.3 and 32.5 
respectively while a mean age of seronegative men was 28.6 and 
35.1 for women. Difference in mean age between seropositive 
and seronegative men was statistically significant at 95% level 
 Virus IgG 
antibodies
  
 HSV VZV CMV
Npositive/Ntotal 762/1149 668/895 1098/1529
% (Npositive/Ntotal ) 66.32 74.75 71.81
95% confidence interval 
(Npositive/Ntotal )
66.19-66.45 74.57-74.93 71.71-71.91
Age  (IgGpositive) mean 
± SD
32.47 ± 23.50 32.88 ± 23.45 31.75 ± 23.47
Age (IgGnegative) mean 
± SD
31.41 ± 23.01 30.64 ± 22.74 32.21 ± 23.35
p-value for difference in 
mean age 0.47 0.21 0.73
Table 1 Herpes virus seroprevalence. 
Table 2 Relationship between presence of herpes virus IgG antibodies, 
and age and sex.
 
HSV                
VZV                
CMV
  
IgG positive women n % 421 (55.2) 373 (55.7) 595 (54.1)
IgG positive men n % 341 (44.7) 295 (44.1) 503 (45.8)
Age IgGpositive M 32.35 ± 23.67 32.35 ± 23.87 30.51 ± 23.01
mean ±  SD    
Age IgGpositive W 32.56 ± 23.38 33.30 ± 23.13 32.80 ± 23.82
mean ±  SD    
p-value for difference in 
mean age 0.9 0.6 0.1
Age IgGnegative M 28.62 ± 22.32 30.75 ± 22.17 32.47 ± 22.97
 mean ±  SD    
Age IgGnegative W 35.16 ± 23.46 30.50 ± 23.58 31.29 ± 23.81
Mean  ±  SD    
p-value for difference in 
mean age 0.006 0.93 0.8
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and we found the same results for women. As shown in Table 
3, in our population seroprevalence for HSV1-2 increase from 
childhood (66%) to adolescence (69%) because children showed 
antibodies against HSV1-2 or for infection or for antibodies 
passively acquired from maternal immunity and decrease in 
adults ≥ 20 (50%). The decrease trend in seropositivity for HSV1-
2, above all in adults is due to the improvement of prevention as 
already observed in other countries. Furthermore, as shown in 
Table 4. In table  4 the multiple logistic regression demonstrated 
that, for HSV1-2, gender was statistically significant while 
lower significance was associated with age. Collected data 
showed  that women are more susceptible to HSV1-2 infections, 
predominantly as genital infection, because mucosal surfaces of 
external genitalia are more vulnerable even if in this study we 
didn’t distinguish orolabial infections from genital infections.
The results for VZV antibodies detection were reported in Table 
1. 668 were seropositive (74,7%)  and 227 seronegative for 
VZV with a mean age of 32.8 an 30.6 respectively. Among 668 
seropositive VZV patients, 295 (44%) were men and 373 (56%) 
were women with a mean age of 32.3 and 33.3 years respectively 
while between seronegative patients the mean age was in 30.7 
and 30.5 respectively showing not significant differences in mean 
ages as reported in Table 2. We could notice that seropositivity 
is higher between women than between men even if the mean 
age of seropositivity is comparable. As shown in Table 3 the vast 
majority acquisition of VZV antibodies was observed in children 
showing a seropositivity of 74.3, 72.6, and 50% respectively. In 
contrast with previous studies in which Nardone  et al. 2007 
reported that in all countries studied over 50% of children 
0-5 years and 90% adolescents 10-15  were seropositive for 
VZV except in Italy where was reported only 38% and 78% 
respectively, in our study we showed an early immunization of 
young population maybe due to better vaccination  programmes 
as shown well in tab. 4 in which we demonstrated with multiple 
logistic regression that age was important for acquiring infection 
whereas gender was less significant.
A larger number of patients was tested for CMV from our 
population. As reported in Table 1, between all patients analysed 
for CMV infection 1098 were seropositive (71%)  and 431 were 
seronegative with a mean age of 31.8 and 32.2 years respectively. 
We noticed, as showed  in Table 2, that on 1098 seropositive 
patients, 503 (46%) were men and 595 (54%) were women with 
a mean age of 30.5 and 32.8 respectively while seronegative 
patients men had a mean age of 32.5 and women of 31.3 years. 
Also in the case of CMVs seropositivity is higher between women 
than in men even if the mean age of seropositivity is comparable 
for both. As reported in Table 3, seroprevalence was higher in 
children from 1 to 9 years and adolescent between 10 and 19 
years decreased in adults 72.72 and 50% respectively,  showing 
that in our region the first infection  for CMV was age-dependent. 
As shown in Table 4, the multiple logistic regression demonstrated 
that, for CMV, age was not statistically significant, while gender 
was significant for acquiring infection.
We observed, moreover, that 665/1854 patients were tested for 
all three viruses and 257 were seropositive for all three, 187 for 
two of them, 100 for only one and 100 seronegative. As shown 
in Table 5a, the multiple logistic regression demonstrated that, 
for them, age was statistically significant, with a p-value < .0001.
A final analysis about these selected patients was made 
considering a multiple Poisson Regression Analysis, in order 
to establish the statistical significance of how many different 
kinds of seropositivity (HSV1-2, VZV, CMV) were acquired by the 
patients vs. the gender and the age. The results in Table 5b, show 
that gender is now the more significant risk factor. 
Discussion
This study is the first, to our knowledge, to report the comparative 
seroepidemiology among HHV in Southern Italy. Few data are 
available on HSV1-2, VZV, CMV seroprevalence in Italy. The 
main importance of this study is that the detection of specific 
antibodies against HHV was conducted on samples randomly 
collected from a general population among both female and male 
of different age and not in subgroups even if some age groups are 
numerically different depending on the subjects coming to the 
Hospital. 
Previous studies in Europe and USA reported that women have 
a high seropositivity against HSV1-2 than men probably because 
they are more biologically susceptible to HSV infections [12-14]. 
We found females had a higher risk of HSV1-2 infection compared 
to males in South Italy agreeing with previous studies in other 
countries. This may reflect the differential role of gender on 
clinical presentation, with men more likely to have asymptomatic 
HSV1-2 infection and could result in higher rates of male to 
female transmission [15-17].
 HSV1-2 VZV CMV
Age % (95%CI) % (95%CI) % (95%CI)
Children (1-9)
65.8 74.3 72.6
(65.3-66.4) (73.5-75.1) (72.2-73.1)
Adolescent (10-19)
68.5 72.6 72.4
(67.6-69.3) (71.5-73.6) (71.8-73.1)
Adult ( ≥ 20)
50 50 50
(49.8-50.1) (49.8-50.2) (49.9-50.1)
Table 3 Seroprevalence of HSV1-2, VZV, CMV by demographic variable. 
p-value is <0.0001 for each virus separately.
HSV1-2 VZV CMV
OR 
(95%CI)
p-value OR  
(95%CI)
p-value OR 
(95%CI)
p-value
Age 1 (0.9-1)
0.8 1.1(1.06-
1.1)
<.0001 1 (0.9-1) 0.69
Gender
1.5 (1.3-
1.8)
<0.0001
0.8 (0.6-
1.2)
0.75 
(1.06-
0.9)
0.01
Table 4 Multiple logistic regression of two risk factors for herpes simplex 
virus, varicella zoster virus and cytomegalovirus.
Table 5 Multiple logistic regression and multiple Poisson Regression 
Analysis of two risk factors for herpes simplex virus, varicella zoster virus 
and cytomegalovirus.
 
HSV1-2; VZV HSV1-2; VZV
CMV CMV
 OR (95%CI) p-value OR  (95%CI) p-value
Age 1.07 (1.06-1.08) <.0001 1 (0.99-1.01) 0.98
Gender 0.82 (10.56-1.22) 0.33 0.87 (0.78-0.97) <.0001
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Similar to other countries in Europe, varicella immunity in Italy 
is acquired gradually starting in early age, showing an increase 
around 3-5 years because in this age they are increasing 
possibilities for exposure and at about six years, they are already 
immune at school entry. Studies demonstrated that in 11 European 
countries with a temperate climate, VZV seroprevalence shows 
rapid increase during the first decade of life, while in tropical and 
subtropical areas, varicella affect mainly adolescents and adults 
[18-20]. Over than 90% of children were seropositive for VZV 
at 15 years with a lower proportions of seropositive individual 
at 5-years-old children in Italy (38%) and in Poland (48%) and a 
highest proportion in Netherlands (95-97%). The wide variation 
in transmissibility observed in different European countries 
is due to varying population densities, social mixing, climate 
differences. In our study, the proportion of immunized patients 
increase by age even if the immunity gained through vaccination 
is not considered to affect the results of our study since so far the 
vaccine was not widely used.
CMV prevalence increases gradually with age so that at old age 
the majority of people in South Italy are infected and with a 
higher females compared to males. The increasing age associated 
with increased seroprevalence for proportion of CMV is in line 
with reports of a significant rate of seroconversion in adults 
[21]. We noticed a higher incidence of infection in adult women 
than men. Furthermore, the increasing seroprevalence by age 
is in contrast with VZV for which over 50% of the population 
is infected at young age but is comparable with HSV1-2 with a 
slow increase age-specific seroprevalence. The main implication 
is that the majority of CMV infections is not only caused by 
transmission among children after primary infection, but also by 
older subjects going through one or more reactivation episodes. 
A corollary is that persistence of CMV in the population is not 
possible with transmission from primary infected persons only, 
and is dependent on infectious reactivation. 
Our sampling is subject to a selection bias because samples 
were collected from people seeking medical helps, limiting 
generalization of results. Convenience of this kind of study is less 
costly, time-consuming and render easier the process to obtain 
samples. To increase study validity, we analyzed samples coming 
from a big hospital that reaches patients from all south Italy to 
receive both primary and hospital care. A high proportion of 
susceptible individuals in certain age of groups detected in our 
study, underlines a need to revise vaccine recommendations 
and to consider the need of a screening above all between 
non-immune women before pregnancy but also between all 
susceptible individuals because at older ages there is an increase 
in the risk of complications.
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